Arctic Bioscience AS's quarterly market cap
increased
from Dec. 2024 (kr46.43 Mil) to Jun. 2025 (kr91.05 Mil) but then
declined
from Jun. 2025 (kr91.05 Mil) to Dec. 2025 (kr88.42 Mil).
Arctic Bioscience AS's annual market cap
declined
from Dec. 2023 (kr266.39 Mil) to Dec. 2024 (kr46.43 Mil) but then
increased
from Dec. 2024 (kr46.43 Mil) to Dec. 2025 (kr88.42 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Arctic Bioscience AS's Enterprise Value for Today is kr149.11 Mil.
Arctic Bioscience AS (OSL:ABS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Arctic Bioscience AS Market Cap Related Terms
Arctic Bioscience AS Market Cap Historical Data
* Premium members only.
The historical data trend for Arctic Bioscience AS's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:ABS vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Arctic Bioscience AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arctic Bioscience AS Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Arctic Bioscience AS's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Arctic Bioscience AS's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arctic Bioscience AS (OSL:ABS) has a Market Cap of kr85.99 Mil as of Jul. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arctic Bioscience AS and its competitors. According to the industry distribution chart, Arctic Bioscience AS ranks #1221 out of 1422 companies in the Biotechnology industry, placing it in the top 85.9%.
Is Arctic Bioscience AS's Market Cap too high?
Arctic Bioscience AS's current Market Cap is kr85.99 Mil. Based on the distribution chart, Arctic Bioscience AS ranks #1221 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arctic Bioscience AS has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arctic Bioscience AS ranks #1221 out of 1422 companies for Market Cap. This places Arctic Bioscience AS in the lower half of its industry. The industry median Market Cap is 120.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.54, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arctic Bioscience AS and its competitors. For the Biotechnology industry, the median Market Cap is 120.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arctic Bioscience AS's current Market Cap is kr85.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr10.62, compared to a current price of kr3.19 — trading 70% below its estimated fair value. The current Market Cap is kr85.99 Mil. Arctic Bioscience AS's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current Market Cap is kr85.99 Mil as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?
Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued.
The current stock price of kr3.19 is trading 70% below its estimated GF Value™ of kr10.62.
GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.
Key valuation signals for OSL:ABS:
Market Cap: kr85.99 Mil
GF Value™: kr10.62 vs. price of kr3.19 (70% below fair value)
No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
55GF Score
Get the complete analysis for OSL:ABS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ABS has been successfully added to your 
